title: An open-label trial of nefazodone in high comorbidity panic disorder.
abstract: BACKGROUND
  Nefazodone is a recently marketed compound with demonstrated efficacy in major depression. This study was undertaken to assess the efficacy and safety of nefazodone in a sample of panic disorder patients with a high degree of depressive comorbidity.
  
  
  METHODS
  Fourteen patients were screened for entry into an open 8-week trial of nefazodone clinically titrated between 200-600 mg. Patients fulfilled DSM-III-R criteria for panic disorder and were allowed to enter with concurrent diagnoses of major depression, dysthymia, generalized anxiety disorder, and depression NOS. Primary outcome measures included panic attack frequency and severity and the Clinical Global Impression scale.
  
  
  RESULTS
  At Week 8 of treatment, 10/14 patients (71%) were judged to be much or very much improved with study treatment. Panic attack frequency decreased from a mean of 5.4 at baseline to 2.1 at Week 8, reaching significance by Week 8 (p < .05) as did decreases in phobic anxiety. Improvement in panic attack severity, phobic avoidance, HAM-D, HAM-A, CGI-Severity, and Sheehan Disability Scale scores was significant by Week 4. Five of the 8 patients with comorbid major depression were responders, as were 3/5 patients with generalized anxiety disorder comorbidity. Five of 6 patients with pure panic or minor depressive symptoms responded to the study treatment. None of the patients withdrew because of side effects of nefazodone.
  
  
  CONCLUSIONS
  This report presents preliminary evidence for the efficacy and tolerability of nefazodone in panic disorder and panic with comorbid depression or depressive symptoms.
authors.affiliation: Department of Psychiatry, University of Pennsylvania, Philadelphia 19104-2649, USA.
authors.forename: N A
authors.initials: NA
authors.lastname: DeMartinis
authors.forename: E
authors.initials: E
authors.lastname: Schweizer
authors.forename: K
authors.initials: K
authors.lastname: Rickels
mesh_terms: D000328:Adult; D018687:Antidepressive Agents, Second-Generation / Q000009:adverse effects / Q000627:therapeutic use*; D001008:Anxiety Disorders / Q000188:drug therapy / Q000453:epidemiology / Q000523:psychology; D015897:Comorbidity; D003863:Depression / Q000188:drug therapy / Q000453:epidemiology / Q000523:psychology; D003866:Depressive Disorder / Q000188:drug therapy* / Q000453:epidemiology / Q000523:psychology; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D016584:Panic Disorder / Q000188:drug therapy* / Q000453:epidemiology / Q000523:psychology; D010879:Piperazines; D011569:Psychiatric Status Rating Scales; D012720:Severity of Illness Index; D016896:Treatment Outcome; D014230:Triazoles / Q000009:adverse effects / Q000627:therapeutic use*
chemical_list: D018687:Antidepressive Agents, Second-Generation; D010879:Piperazines; D014230:Triazoles; C051752:nefazodone